 The purpose of this study is to determine whether baricitinib 4 milligram mg once daily is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis RA who have had an inadequate response to a tumor necrosis factor TNF inhibitor, despite ongoing treatment with conventional disease-modifying antirheumatic drugs cDMARDs. 